relation: http://repositorio.uneatlantico.es/id/eprint/6483/ canonical: http://repositorio.uneatlantico.es/id/eprint/6483/ title: Cost-effectiveness of transdiagnostic group cognitive behavioural therapy versus group relaxation therapy for emotional disorders in primary care (PsicAP-Costs2): Protocol for a multicentre randomised controlled trial creator: Moreno-Peral, Patricia creator: González-Blanch, César creator: Barrio-Martínez, Sara creator: Priede, Amador creator: Martínez-Gómez, Sandra creator: Pérez-García-Abad, Saioa creator: Miras-Aguilar, María creator: Ruiz-Gutiérrez, José creator: Muñoz-Navarro, Roger creator: Ruiz-Rodríguez, Paloma creator: Medrano, Leonardo A. creator: Prieto-Vila, Maider creator: Carpallo-González, María creator: Aguilera-Martín, Ángel creator: Gálvez-Lara, Mario creator: Cuadrado, Fátima creator: Moreno, Eliana creator: García-Torres, Francisco creator: Venceslá, José F. creator: Corpas, Jorge creator: Jurado-González, Francisco J. creator: Moriana, Juan A. creator: Cano-Vindel, Antonio subject: Psicología description: Several randomised controlled trials (RCT) have demonstrated the superiority of transdiagnostic group cognitive-behavioural therapy (TD-CBT) to treatment as usual (TAU) for emotional disorders in primary care. To date, however, no RCTs have been conducted to compare TD-CBT to another active intervention in this setting. Our aim is to conduct a single-blind RCT to compare group TD-CBT plus TAU to progressive muscle relaxation (PMR) plus TAU in adults (age 18 to 65 years) with a suspected emotional disorder. We expect that TD-CBT + TAU will be more cost-effective than TAU + PMR, and that these gains will be maintained at the 12-month follow-up. Seven therapy sessions (1.5 hours each) will be offered over a 24-week period. The study will be carried out at four primary care centres in Cantabria, Spain. The study will take a societal perspective. Psychological assessments will be made at three time points: baseline, post-treatment, and at 12-months. The following variables will be evaluated: clinical symptoms (anxiety, depression, and/or somatic); functioning; quality of life (QoL); cognitive-emotional factors (rumination, worry, attentional and interpretative biases, emotion regulation and meta-cognitive beliefs); and satisfaction with treatment. Data on health service use, medications, and sick days will be obtained from electronic medical records. Primary outcome measures will include: incremental cost-effectiveness ratios (ICER) and incremental cost-utility ratios (ICURs). Secondary outcome measures will include: clinical symptoms, QoL, functioning, and treatment satisfaction. Bootstrap sampling will be used to assess uncertainty of the results. Secondary moderation and mediation analyses will be conducted. Two questionnaires will be administered at sessions 1, 4, and 7 to assess therapeutic alliance and group satisfaction. If this trial is successful, widespread application of this cost-effective treatment could greatly improve access to psychological treatment for emotional disorders in the context of increasing demand for mental healthcare in primary care. date: 2023 type: Artículo type: PeerReviewed format: text language: en rights: cc_by_4 identifier: http://repositorio.uneatlantico.es/id/eprint/6483/1/journal.pone.0283104.pdf identifier: Artículo Materias > Psicología Universidad Europea del Atlántico > Investigación > Producción Científica Abierto Inglés Several randomised controlled trials (RCT) have demonstrated the superiority of transdiagnostic group cognitive-behavioural therapy (TD-CBT) to treatment as usual (TAU) for emotional disorders in primary care. To date, however, no RCTs have been conducted to compare TD-CBT to another active intervention in this setting. Our aim is to conduct a single-blind RCT to compare group TD-CBT plus TAU to progressive muscle relaxation (PMR) plus TAU in adults (age 18 to 65 years) with a suspected emotional disorder. We expect that TD-CBT + TAU will be more cost-effective than TAU + PMR, and that these gains will be maintained at the 12-month follow-up. Seven therapy sessions (1.5 hours each) will be offered over a 24-week period. The study will be carried out at four primary care centres in Cantabria, Spain. The study will take a societal perspective. Psychological assessments will be made at three time points: baseline, post-treatment, and at 12-months. The following variables will be evaluated: clinical symptoms (anxiety, depression, and/or somatic); functioning; quality of life (QoL); cognitive-emotional factors (rumination, worry, attentional and interpretative biases, emotion regulation and meta-cognitive beliefs); and satisfaction with treatment. Data on health service use, medications, and sick days will be obtained from electronic medical records. Primary outcome measures will include: incremental cost-effectiveness ratios (ICER) and incremental cost-utility ratios (ICURs). Secondary outcome measures will include: clinical symptoms, QoL, functioning, and treatment satisfaction. Bootstrap sampling will be used to assess uncertainty of the results. Secondary moderation and mediation analyses will be conducted. Two questionnaires will be administered at sessions 1, 4, and 7 to assess therapeutic alliance and group satisfaction. If this trial is successful, widespread application of this cost-effective treatment could greatly improve access to psychological treatment for emotional disorders in the context of increasing demand for mental healthcare in primary care. metadata Moreno-Peral, Patricia; González-Blanch, César; Barrio-Martínez, Sara; Priede, Amador; Martínez-Gómez, Sandra; Pérez-García-Abad, Saioa; Miras-Aguilar, María; Ruiz-Gutiérrez, José; Muñoz-Navarro, Roger; Ruiz-Rodríguez, Paloma; Medrano, Leonardo A.; Prieto-Vila, Maider; Carpallo-González, María; Aguilera-Martín, Ángel; Gálvez-Lara, Mario; Cuadrado, Fátima; Moreno, Eliana; García-Torres, Francisco; Venceslá, José F.; Corpas, Jorge; Jurado-González, Francisco J.; Moriana, Juan A. y Cano-Vindel, Antonio mail SIN ESPECIFICAR, cesar.gonzalezblanch@uneatlantico.es, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR (2023) Cost-effectiveness of transdiagnostic group cognitive behavioural therapy versus group relaxation therapy for emotional disorders in primary care (PsicAP-Costs2): Protocol for a multicentre randomised controlled trial. PLOS ONE, 18 (3). e0283104. ISSN 1932-6203 relation: http://doi.org/10.1371/journal.pone.0283104 relation: doi:10.1371/journal.pone.0283104 language: en